Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091645 | 1.00 | GAA (0.37) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL13091640 | 0.87 | KLK7 (0.37) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3075369 | 0.87 | KLK7 (0.37) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL13101404 | 0.87 | KLK7 (0.37) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3075365 | 0.87 | KLK7 (0.37) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL11714017 | 0.80 | AKT1 (0.43) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL11714025 | 0.80 | AKT1 (0.43) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL14024599 | 0.79 | KLK7 (0.36) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL13101401 | 0.79 | KLK7 (0.39) | GAAFFAR2POLBRAB9A | |
| SCHEMBL3076424 | 0.79 | KLK7 (0.39) | GAAFFAR2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266675-A1 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266675-A1 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM | LIPG, VEGFA, LIPE | GAA 1720/4885ALDH1A1 4419/4885MEN1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.